A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...

Investigators examined GLP-1 receptor agonist real-world effectiveness and safety in kidney transplant recipients with diabetes.

Key Takeaways Real-world results with weight-loss drugs aren’t as impressive as those in clinical trialsClinic patients ...

Nearly 75% of US adults are overweight or obese*, but the new GLP-1 pharmaceuticals are out of reach for many due to lack of ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite ...